Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and Fallopian tube and primary carcinoma of the peritoneum
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and Fallopian tube and primary carcinoma of the peritoneum
复制标题
DOI：
10.1200/jco.2001.19.7.1901
复制
发表时间：
2001-04-01
影响因子：
45.3
通讯作者：
Belinson, J
中科院分区：
文献类型：
--
作者：
Markman, M;Kennedy, A;Belinson, J
目的：晚期卵巢癌的标准化疗目前包括铂类药物（通常为卡铂）和紫杉醇。由于多西他赛是铂类耐药卵巢癌的活性药物，因此评价卡铂和多西他赛联合治疗的毒性和疗效是相关的。患者和方法：克利夫兰诊所Taussig癌症中心的妇科肿瘤项目进行了卡铂的II期试验（6的浓度-时间曲线下面积）和多西他赛（60 mg/m2），每3周一次，共6个疗程，在卵巢癌、输卵管癌和原发性腹膜癌患者中，结果：50例患者（中位年龄57岁，范围44 - 81岁）进入试验（47例既往未接受过化疗）。我们的毒性研究结果包括以下内容：4级中性粒细胞减少（64%的患者）;超敏反应134%，没有需要停止治疗）;周围神经病变（6%），我们有客观的反应为32 42（81%）评估patients.Conclusion：卡铂和多西他赛的组合是高度活跃的卵巢癌，主要的毒性是骨髓抑制。超敏反应是常见的，但不妨碍继续治疗。在本试验中使用的剂量和时间表中，神经毒性不常见。确定该方案在常规临床实践中的作用将需要进行随机对照临床试验。(C)2001年，美国临床肿瘤学会。
Purpose: Standard chemotherapy for advanced ovarian cancer currently includes a platinum agent (usually carboplatin) and paclitaxel. Because docetaxel is an active agent in platinum-resistant ovarian cancer, it is relevant to evaluate both the toxicity and efficacy of the combination of carboplatin and docetaxel in this clinical setting.Patients and Methods: The Gynecologic Oncology Program of the Cleveland Clinic Taussig Cancer Center conducted a phase II trial of carboplatin (area under the concentration-versus-time curve of 6) and docetaxel (60 mg/m(2)), delivered every 3 weeks for six courses, in patients with ovarian and fallopian tube cancers and primary carcinoma of the peritoneum who had either received no prior chemotherapy or had experienced a treatment-free interval of greater than 2 years before developing disease recurrence.Results: Fifty patients (median age, 57 years; range, 44 to 81 years) entered the trial (47 had had no prior chemotherapy). Our toxicity findings included the following: grade 4 neutropenia (64% of patients); hypersensitivity reactions 134%, none requiring discontinuation of therapy); peripheral neuropathy (6%), We had objective responses for 32 of 42 (81%) assessable patients.Conclusion: The combination of carboplatin and docetaxel is highly active in ovarian cancer, with the major toxicity being bone marrow suppression. Hypersensitivity reactions are frequent but do not prevent continuation of treatment. With the dose and schedule employed in this trial, neurotoxicity is uncommon. Defining a role for this regimen in routine clinical practice will require the conduct of randomized controlled clinical trials. (C) 2001 by American Society of Clinical Oncology.